107 related articles for article (PubMed ID: 4102055)
1. Tolbutamide.
Helps EP
Lancet; 1971 May; 1(7705):912-3. PubMed ID: 4102055
[No Abstract] [Full Text] [Related]
2. [Proceedings: Cellular calcium and insulin secretion. Morphologic studies of B-cells in the mouse following tolbutamide and diazoxide administration].
Schäfer HJ; Klöppel G
Verh Dtsch Ges Pathol; 1974; 58():490. PubMed ID: 4618000
[No Abstract] [Full Text] [Related]
3. Insulin and the heart.
Csapó G
Lancet; 1970 Feb; 1(7644):471. PubMed ID: 4189781
[No Abstract] [Full Text] [Related]
4. [Tolbutamide and coronary heart disease].
Paasikivi J
Duodecim; 1971; 87(21):1405-8. PubMed ID: 5114598
[No Abstract] [Full Text] [Related]
5. Conditioned insulin secretion and hypoglycemia following repeated injections of tolbutamide in rats.
Woods SC; Alexander KR; Porte D
Endocrinology; 1972 Jan; 90(1):227-31. PubMed ID: 5009061
[No Abstract] [Full Text] [Related]
6. Hypoglycemia--tolbutamide induced. Prolonged tolbutamide induced hypoglycemia in the postoperative patient.
Drevets CC
J Kans Med Soc; 1969 Feb; 70(2):49-51 passim. PubMed ID: 5763154
[No Abstract] [Full Text] [Related]
7. Biological activities of tolbutamide and its metabolites. A dissociation of insulin-releasing and hypoglycemic activity.
Feldman JM; Lebovitz HE
Diabetes; 1969 Aug; 18(8):529-37. PubMed ID: 5808747
[No Abstract] [Full Text] [Related]
8. The tolbutamide controversy.
Compr Ther; 1975 May; 1(1):19-20. PubMed ID: 1222531
[No Abstract] [Full Text] [Related]
9. Interaction of tolbutamide and chloramphenicol in diabetic patients.
Brunová E; Slabochová Z; Platilová H; Pavlik F; Grafnetterová J; Dvorácek K
Int J Clin Pharmacol Biopharm; 1977 Jan; 15(1):7-12. PubMed ID: 838527
[TBL] [Abstract][Full Text] [Related]
10. Editorial: Oral hypoglycemic drugs.
Scoville AB
J Tenn Med Assoc; 1975 Apr; 68(4):319-20. PubMed ID: 1117723
[No Abstract] [Full Text] [Related]
11. Controlled clinical trials and the tolbutamide controversy.
Lavietes PH
Conn Med; 1971 Apr; 35(4):271-2. PubMed ID: 4927818
[No Abstract] [Full Text] [Related]
12. [Severe hypoglycemia due to Dirastan (tolbutamide) in a diabetic with chronic renal failure].
Bures J; Fixa B; Kaut V; Herout V; Hrncír Z
Vnitr Lek; 1982 Jul; 28(7):678-84. PubMed ID: 7112992
[No Abstract] [Full Text] [Related]
13. [Heart death and oral antidiabetics; the last judgement].
Touber JL
Ned Tijdschr Geneeskd; 1975 Sep; 119(39):1506-8. PubMed ID: 1101083
[No Abstract] [Full Text] [Related]
14. Similar physiological and symptomatic responses to sulphonylurea and insulin induced hypoglycaemia in normal subjects.
Peacey SR; George E; Rostami-Hodjegan A; Bedford C; Harris N; Hardisty CA; Tucker GT; Macdonald IA; Heller SR
Diabet Med; 1996 Jul; 13(7):634-41. PubMed ID: 8840097
[TBL] [Abstract][Full Text] [Related]
15. Tolbutamide: another view.
Nahum LH
Conn Med; 1971 Apr; 35(4):272-3. PubMed ID: 5108037
[No Abstract] [Full Text] [Related]
16. Letter: Phenylbutazone-tolbutamide drug interaction.
Tannenbaum H; Anderson LG; Soeldner JS
N Engl J Med; 1974 Feb; 290(6):344. PubMed ID: 4809290
[No Abstract] [Full Text] [Related]
17. Tolbutamide and the heart.
Ricketts HT
JAMA; 1972 Nov; 222(9):1179-80. PubMed ID: 4678067
[No Abstract] [Full Text] [Related]
18. Insulin and the heart.
Taylor SH
Lancet; 1970 Feb; 1(7644):471. PubMed ID: 4189782
[No Abstract] [Full Text] [Related]
19. [Incidence and severity of treatment-induced hypoglycemias in diabetics].
Hasslacher C; Wahl P
Dtsch Med Wochenschr; 1971 Nov; 96(46):1787-91. PubMed ID: 5000535
[No Abstract] [Full Text] [Related]
20. Increasing the decrement in insulin secretion improves glucagon responses to hypoglycemia in advanced type 2 diabetes.
Israelian Z; Gosmanov NR; Szoke E; Schorr M; Bokhari S; Cryer PE; Gerich JE; Meyer C
Diabetes Care; 2005 Nov; 28(11):2691-6. PubMed ID: 16249541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
